[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630047":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":43,"collaborators":19,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":19,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":19,"enrollmentInfo":54,"targetDuration":19,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":19,"overallStatus":29,"whyStopped":19,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"TQB3205 capsules","EXPERIMENTAL","Single or continuous administration, 6-36 mg each time; TQB3205 capsule is taken orally once a day on an empty stomach, and each cycle is 21 days.",[13],"Drug: TQB3205 capsules",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","TQB3205 capsule is a targeted protein degrader",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Jihui Hao, Doctor","CONTACT","022-23340123-3070","haojihui@tjmuch.com",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Tianjin Medical University Cancer Institute & Hospital","RECRUITING","Tianjin","Tianjin Municipality","300060","China","CN",{"type":36,"coordinates":37},"Point",[38,39],117.17667,39.14222,{"lat":39,"lon":38},[42],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},{"type":44,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100630047","phase-1-clinical-trial-of-tqb3205-capsule-in-subjects-with-advanced-malignant-tumors-100630047",false,"NCT07482592","Clinical Trial of TQB3205 Capsule in Subjects With Advanced Malignant Tumors","Phase I Clinical Trial to Evaluate the Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3205 Capsule in Subjects With Advanced Malignant Tumors","Inclusion Criteria:\n\n* Subjects voluntarily joined the study, signed informed consent form, and with good compliance.\n* ≥18 years old; Eastern Cooperative Oncology Group (ECOG) physical status: 0-1; at least 3 months expected survival period.\n* At least 1 measurable lesion for efficacy evaluation.\n* The function of main organs is normal.\n* Women of childbearing age should agree to use effective contraceptive measures during the study period and within 6 months after the end of the study, and have a negative serum or urine pregnancy test within 7 days before enrollment in the study; Men should agree to use effective contraceptive measures during the study period and within 6 months after the end of the study period.\n\nExclusion Criteria:\n\n* Individuals who have undergone major surgical treatment, significant traumatic injury, or major surgery during the expected study treatment period within 4 weeks prior to the first medication (excluding surgeries specified in the protocol), or have long-term untreated wounds or fractures. (Major surgery is defined as surgery at level 3 or above in the National Surgical Classification Catalogue 2022 edition);\n* Subjects who experience any bleeding or bleeding events ≥ CTC AE grade 3 within 4 weeks prior to the first administration.\n* Active syphilis infected individuals in need of treatment\n* Individuals with a history of abuse of psychotropic drugs who are unable to quit or have mental disorders;\n* Individuals who are preparing for or have previously undergone allogeneic bone marrow transplantation or solid organ transplantation;\n* History of hepatic encephalopathy;\n* Active or uncontrolled infections (≥ CTC AE level 2 infection);\n* Patients with renal failure requiring hemodialysis or peritoneal dialysis;\n* History of immunodeficiency, including HIV positivity or other acquired or congenital immunodeficiency diseases;\n* Individuals with epilepsy who require treatment;\n* Poor control of diabetes (assessed by the investigator);\n* Known to be allergic to research drugs or excipients;\n* Those who have participated in and used other anti-tumor clinical trial drugs within 4 weeks before the first medication;\n* According to the researcher's judgment, there is a situation that seriously endangers the safety of the subjects or affects their ability to complete the study.","ALL","18 Years",{"count":55,"type":56},156,"ESTIMATED","INTERVENTIONAL",[59],"PHASE1","The trial was divided into two phases: dose escalation and dose expansion. The dosing regimens were single-dose study and continuous dosing study. A single-center, open, non-randomized, single-arm clinical trial design was adopted. Subjects with advanced malignant tumors were selected to take TQB3205 capsules orally to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TQB3205 capsules.",[62],"Advanced Malignant Cancer","2026-04-17",{"date":65,"type":66},"2026-04-20","ACTUAL",{"date":68,"type":66},"2026-04-15",{"date":70,"type":56},"2028-12",{"name":5,"class":6},1]